Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism

A Randomized Trial

View larger version (10K): [in this window] [in a new window]   Figure 1. Risk for venous thromboembolism (VTE) in prespecified subgroups. *Limited to the 3306 participants for whom homocysteine was measured at baseline. Homocysteine level >13.8 µmol/L.

View larger version (10K): [in this window] [in a new window]   Figure 2. Cumulative proportion of participants with venous thromboembolism.

View this table: [in this window] [in a new window]   Appendix Table. Baseline Characteristics of Participants Who Did and Did Not Have Plasma Homocysteine Measured at Baseline*